The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression

OncoImmunology

Volumn 6, Issue 10, 2017, Pages

  Weiss, Julia M ^a,b,c   Guérin, Marion V ^a,b,c   Regnier, Fabienne ^a,b,c   Renault, Gilles ^a,b,c   Galy Fauroux, Isabelle ^d   Vimeux, Lene ^a,b,c   Feuillet, Vincent ^a,b,c   Peranzoni, Elisa ^a,b,c   Thoreau, Maxime ^a,b,c   Trautmann, Alain ^a,b,c   Bercovici, Nadège ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Cooperation; imaging; interferon; myeloid cells; STING; T lymphocytes; tumor regression

Indexed keywords

ALPHA1 INTERFERON; INTERFERON; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; VADIMEZAN;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER TRANSPLANTATION; CAPILLARY DENSITY; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; INTERFERON GENE; KINETICS; MACROPHAGE; NEUTROPHIL; NONHUMAN; POLYMERASE CHAIN REACTION; SPATIOTEMPORAL ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; ULTRASOUND; VASCULARIZATION;

EID: 85026854606     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1346765     Document Type: Article

References (25)

1. Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2016; 22:1875-84; https://doi.org/10.1158/1078-0432.CCR-15-1433
2. Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, Tartour E. Is there still room for cancer vaccines at the era of checkpoint inhibitors. Vaccines 2016; 4:37; PMID:27827885; `https://doi.org/10.3390/vaccines4040037
3. Baguley BC, Siemann DW. Temporal Aspects of the Action of ASA404 (Vadimezan; DMXAA). Expert Opin Investig Drugs 2010; 19:1413-25; PMID:20964495; https://doi.org/10.1517/13543784.2010.529128
4. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-vascular disrupting agents. Cancer Treat Rev 2011; 37:63-74; PMID:20570444; https://doi.org/10.1016/j.ctrv.2010.05.001
5. Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 2005; 116:322-6; PMID:15800918; https://doi.org/10.1002/ijc.21005
6. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004; 90:906-10; PMID:14970872; https://doi.org/10.1038/sj.bjc.6601606
7. Wang L-CS, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen C-JJ, Angel CE, Dunbar PR, Ching L-M. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia N Y N 2009; 11:793-803; https://doi.org/10.1593/neo.09506
8. Fridlender ZG, Jassar A, Mishalian I, Wang L-C, Kapoor V, Cheng G, Sun J, Singhal S, Levy L, Albelda SM. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 2013; 108:1288-97; PMID:23481183; https://doi.org/10.1038/bjc.2013.93
9. Zhao L, Ching L-M, Kestell P, Baguley BC. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002; 87:465-70; PMID:12177785; https://doi.org/10.1038/sj.bjc.6600479
10. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 2002; 86:1937-42; PMID:12085190; https://doi.org/10.1038/sj.bjc.6600368
11. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, Vogel SN. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 2012; 287:39776-88; PMID:23027866; https://doi.org/10.1074/jbc.M112.382986
12. Roberts ZJ, Ching L-M, Vogel SN. IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 2008; 28:133-9; https://doi.org/10.1089/jir.2007.0992
13. Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9; PMID:15951814; https://doi.org/10.1038/ni1213
14. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; https://doi.org/10.1038/nm.3708
15. Shirey KA, Nhu QM, Yim KC, Roberts ZJ, Teijaro JR, Farber DL, Blanco JC, Vogel SN. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol 2011; 89:351-7; PMID:21084628; https://doi.org/10.1189/jlb.0410216
16. Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama K, Dessailly BH, Kuroda E, Akira S, Mizuguchi K, et al. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PloS One 2013; 8:e60038; PMID:23555875; https://doi.org/10.1371/journal.pone.0060038
17. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M-C, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012; 122:899-910; PMID:22293174; https://doi.org/10.1172/JCI45817
18. Thoreau M, Penny HL, Tan K, Regnier F, Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado J-P, et al. Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget 2015; 6:27832-46; PMID:26337837; https://doi.org/10.18632/oncotarget.4940
19. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999; 59:633-8; PMID:9973211
20. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125:3356-64; PMID:26168215; https://doi.org/10.1172/JCI80005
21. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching L-M, Kaiser LR, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005; 65:11752-61; PMID:16357188; https://doi.org/10.1158/0008-5472.CAN-05-1658
22. Sektioglu IM, Carretero R, Bender N, Bogdan C, Garbi N, Umansky V, Umansky L, Urban K, von Knebel-Döberitz M, Somasundaram V, et al. Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. Oncoimmunology 2016; 5:e1204506; PMID:27853636; https://doi.org/10.1080/2162402X.2016.1204506
23. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes Tumor Site-Specific vascular disruption in Murine non-small cell lung cancer, and like the Endogenous Non-Canonical cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, induces M2 Macrophage Repolarization. PLoS One [Internet] 2014 [cited 2016Mar15]; 9:e99988. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062468/
24. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. IFNγ and CCL2 cooperate to redirect Tumor-Infiltrating Monocytes to degrade Fibrosis and enhance chemotherapy efficacy in Pancreatic Carcinoma. Cancer Discov 2016; 6:400-13; PMID:26896096; https://doi.org/10.1158/2159-8290.CD-15-1032
25. + T cells in the airways. Science 2015; 349:aaa4352; PMID:26339033; https://doi.org/10.1126/science.aaa4352